Prof. Mridula Sharma, a retired college principal, battled a life-threatening arrhythmia unresponsive to conventional treatments. After exhausting standard medications, her cardiologist recommended genomic testing. Yoda Diagnostics’ PGx—Cardiovascular panel sequencing revealed a mutation in the MYH7 gene, a known cause of hereditary heart disease. This insight led to targeted therapy, stabilizing her condition and significantly improving her quality of life.
Had Prof. Sharma lacked access to such diagnostics, her fate could have been different. While genomics is mainstream in countries like the US, Yoda Diagnostics was founded to bring this transformative power to India and democratize genomic healthcare.
The State of Genomics in India
Since the first human genome was sequenced in 2003, costs and time have plummeted. Today, sequencing can be completed in a day at a fraction of its original cost. Yet, precision medicine in India remains underutilized due to cost barriers, limited infrastructure, and regulatory constraints.
“Precision medicine is not a futuristic ideal; it’s a present-day necessity,” asserts Dr. Shaik Mohammed Naushad, Chief Scientific Officer at Yoda Diagnostics. The company offers a range of testing panels—from oncology to rare disease diagnostics—tailored for Indian patients. However, limited insurance coverage means the financial burden often falls on patients, making these life-saving advancements inaccessible for many.
Bridging the Gap: Yoda Diagnostics’ Commitment to Accessible Genomics
Despite the global genetic testing market surpassing $17 billion, India’s share remains modest at around $60 million. Yoda Diagnostics aims to change this by delivering precise, affordable, and globally benchmarked genetic testing solutions.
Establishing a state-of-the-art genomic lab in Hyderabad was no small feat. Founder Sudhakar Kancharla, inspired by American diagnostic models, sought to replicate their advanced framework in India, focusing on accessibility and affordability.
“For India, we need more than technology; we need accessibility and affordability,” says Kancharla, who previously established diagnostic labs and IT companies in the US. His vision extends beyond diagnostics—he advocates for genomic health as a standard component of patient care.
Leading the Charge: Innovation, Quality, and Patient Care
Yoda Diagnostics specializes in oncology panels, cardiovascular diagnostics, and rare disease panels. The company collaborates closely with clinicians to deliver precise, actionable results, adhering to global accreditation standards like NABL and ICMR. Their proprietary tools, designed per ACMG guidelines, provide germline and somatic genetic analysis with unmatched precision.
Founder’s Vision: A Personal Journey to Precision Medicine
Sudhakar Kancharla’s journey is both inspiring and personal. Born and raised in India, he pursued molecular biology in the US, working at top healthcare institutions. His expertise in molecular genetics and genomics in oncology and rare diseases motivated him to return to India to make precision medicine accessible.
“We saw the power of genomics in transforming patient care and wanted to bring it to the average Indian patient,” Kancharla shares. Yoda Diagnostics embodies this commitment through education initiatives, collaborations with hospitals, and awareness programs.
Building India’s Genomic Database: A Pioneering Initiative
For genomics to reach its full potential, building a comprehensive genetic database is crucial. Precision medicine relies on identifying genetic variations across populations, yet most global genomic databases are skewed toward Western populations, leaving India’s genetic diversity largely unexplored.
Yoda Diagnostics is addressing this gap by partnering with researchers to construct a robust Indian genomic database. This initiative aims to enhance patient care and advance research, particularly for conditions prevalent in South Asian communities.
The Road Ahead: Paving the Way for India’s Genomic Revolution
Mainstreaming precision medicine in India faces challenges—regulatory hurdles, data privacy concerns, and affordability. Yet, with the push for a national digital health ecosystem and genomic initiatives by Yoda Diagnostics, the future looks promising.
“Our vision is to make genomic testing as routine as an MRI or blood test,” Kancharla affirms. By merging international expertise with a commitment to Indian healthcare, Yoda Diagnostics is paving the way for a genomics-driven future. As awareness grows, India’s genomic revolution is not a distant dream—it’s on the horizon.
This is not just healthcare innovation; it’s a movement to empower every Indian with the knowledge and resources they need to take control of their health—one genome at a time.
If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.
.jpg)
